Here are the 10-K annual reports from Crescent Biopharma, Inc. (CBIO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBIO filings page.
Crescent Biopharma, Inc., now incorporated in the Cayman Islands after a reverse recapitalization with GlycoMimetics, is a clinical-stage oncology company with no approved products and a history of losses. Its strategy centers on CR-001, a PD-1 x VEGF bispecific antibody engineered to mirror the pharmacology of ivonescimab, which has shown superior progression-free survival to pembrolizumab in non-small cell lung cancer. Crescent plans a global Phase 1/2 trial of CR-001 across up to eight solid tumors, along with ADC candidates CR-002, a PD-L1-targeted topoisomerase ADC, and CR-003, an ITGB6-directed topoisomerase ADC licensed from Kelun. The company highlights extensive third-party dependencies and sizable milestone and royalty commitments under its Paragon and Kelun agreements, while targeting multiple trial starts in 2026 and initial data readouts in 2027. As of June 30, 2025, non-affiliate equity was valued at about $177.2 million, with 27,556,767 ordinary shares outstanding as of February 23, 2026.